Review Articles

Liraglutide for the treatment of obesity

Elmien Bronkhorst, Natalie Schellack
South African Family Practice | Vol 58, No 3 : May/June| a4496 | DOI: https://doi.org/10.4102/safp.v58i3.4496 | © 2016 Elmien Bronkhorst, Natalie Schellack | This work is licensed under CC Attribution 4.0
Submitted: 23 May 2016 | Published: 01 May 2016

About the author(s)

Elmien Bronkhorst, Department of Pharmacy, Faculty of Health Sciences, Sefako Makgatho Health Sciences University (SMU), South Africa
Natalie Schellack, Department of Pharmacy, Faculty of Health Sciences, Sefako Makgatho Health Sciences University (SMU), South Africa

Full Text:

PDF (64KB)

Abstract

Obesity and being overweight have become significant global health concerns, and may actually be seen as chronic disease conditions or even as a worldwide epidemic. In addition to the necessary life-style modifications required to effect weight-loss, which constitutes an essential healthcare intervention in this patient population, the use of adjunctive pharmacotherapeutic agents is often required. This article provides an overview of the first injectable treatment option, namely liraglutide, in the management of obesity, or of patients that are overweight in the presence of significant co-morbid conditions.

Keywords

liraglutide; overweight; obesity; weight-loss; incretin; GLP-1; type 2 diabetes mellitus

Metrics

Total abstract views: 2237
Total article views: 2154


Crossref Citations

No related citations found.